CIK 0001710072 · Large accelerated filer
Edgewise Therapeutics, Inc.
Sign in to watch- Ticker
- EWTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 821725586
- Phone
- 720-262-7002
- Business address
- 1715 38TH ST, BOULDER, CO, 80301
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $201,787
- in 1 filing
Net −$201,787. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-10 | Nofi Michael Chief Financial Officer | Option exercise | +10,937 | 10,937 | ||
| 2026-11-10 | Nofi Michael Chief Financial Officer | Sale | −4,442 | $45.43 | $202K | 6,495 |
| 2026-11-10 | Nofi Michael Chief Financial Officer | Option exercise · Restricted Stock Units | −10,937 | 32,813 | ||
| 2026-10-01 | Fox Jonathan C Director | Grant or award | +308 | 25,141 | ||
| 2026-08-13 | Donovan Joanne M. CMO | Sale | −2,919 | $43.41 | $127K | 8,625 |
| 2026-08-12 | Russell Alan J Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +65,000 | 65,000 | ||
| 2026-08-12 | Derakhshan Behrad Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2026-08-12 | Nofi Michael Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +48,750 | 48,750 | ||
| 2026-08-12 | Donovan Joanne M. CMO | Grant or award · Stock Option (Right to Buy) | +65,000 | 65,000 | ||
| 2026-08-12 | MOORE JOHN R General Counsel | Grant or award · Stock Option (Right to Buy) | +65,000 | 65,000 | ||
| 2026-08-12 | Russell Alan J Chief Scientific Officer | Option exercise | +5,781 | 30,336 | ||
| 2026-08-12 | Russell Alan J Chief Scientific Officer | Option exercise | +7,031 | 37,367 | ||
| 2026-08-12 | Russell Alan J Chief Scientific Officer | Sale | −3,238 | $43.68 | $141K | 34,129 |
| 2026-08-12 | Russell Alan J Chief Scientific Officer | Sale | −2,273 | $43.68 | $99K | 31,856 |
| 2026-08-12 | Russell Alan J Chief Scientific Officer | Sale | −390 | $44.46 | $17K | 31,466 |
| 2026-08-12 | Russell Alan J Chief Scientific Officer | Option exercise · Restricted Stock Units | −5,781 | 11,563 | ||
| 2026-08-12 | Russell Alan J Chief Scientific Officer | Option exercise · Restricted Stock Units | −7,031 | 21,094 | ||
| 2026-08-12 | Russell Alan J Chief Scientific Officer | Grant or award · Restricted Stock Units | +32,500 | 32,500 | ||
| 2026-08-12 | Russell Alan J Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +65,000 | 65,000 | ||
| 2026-08-12 | Derakhshan Behrad Chief Business Officer | Option exercise | +5,781 | 29,426 |
Page 1 of 26 · 509 trades